Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Amicus Therapeutics Inc banner

Amicus Therapeutics Inc
NASDAQ:FOLD

Watchlist Manager
Amicus Therapeutics Inc Logo
Amicus Therapeutics Inc
NASDAQ:FOLD
Watchlist
Price: 14.315 USD 0.1% Market Closed
Market Cap: $4.4B
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

FOLD Price Targets Summary
Amicus Therapeutics Inc

Wall Street analysts forecast FOLD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FOLD is 15.81 USD with a low forecast of 14.14 USD and a high forecast of 23.1 USD.

FOLD Lowest Forecast
Wall Street Target
14.14 USD
-1% Downside
FOLD Average Forecast
Wall Street Target
15.81 USD
10% Upside
FOLD Highest Forecast
Wall Street Target
23.1 USD
61% Upside
Lowest
Price Target
14.14 USD
1% Downside
Average
Price Target
15.81 USD
10% Upside
Highest
Price Target
23.1 USD
61% Upside
Amicus Therapeutics Inc Competitors:
Price Targets
LVS
Las Vegas Sands Corp
25% Upside
LVS
Las Vegas Sands Corp
25% Upside

Revenue
Forecast

28% / Year
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
28% / Year
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

For the last 13 years the compound annual growth rate for Amicus Therapeutics Inc's revenue is 28%. The projected CAGR for the next 4 years is 20%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
84% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat
N/A
Past Growth
84% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat

The compound annual growth rate of Amicus Therapeutics Inc's operating income for the next 4 years is 84%.

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-40%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-40%
Average Miss

What are analyst estimates?

See Also

Summary
FOLD intrinsic value, competitors valuation, and company profile.
DCF Valuation
FOLD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
FOLD stock valuation using valuation multiples.
Wall Street Estimates
FOLD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
FOLD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is FOLD's stock price target?
Price Target
15.81 USD

According to Wall Street analysts, the average 1-year price target for FOLD is 15.81 USD with a low forecast of 14.14 USD and a high forecast of 23.1 USD.

What is Amicus Therapeutics Inc's Revenue forecast?
Projected CAGR
20%

For the last 13 years the compound annual growth rate for Amicus Therapeutics Inc's revenue is 28%. The projected CAGR for the next 4 years is 20%.

What is Amicus Therapeutics Inc's Operating Income forecast?
Projected CAGR
84%

The compound annual growth rate of Amicus Therapeutics Inc's operating income for the next 4 years is 84%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 316,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.